Guodong Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Guodong Liang has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
Yuheng Ma
8 shared publicationsLu Ga
7 shared publicationsYan Zhao
7 shared publicationsJinlin Wang
5 shared publicationsXiao Qi
4 shared publicationsXin Gao
4 shared publications
Latest Publications
- 21 July 2026
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 33, 1-23
Research and Development of Small Molecule Fusion Inhibitors Against Viruses
The Type I enveloped viruses (such as HIV, coronavirus, influenza virus, etc.) have caused significant public health events globally, including AIDS, influenza pandemics, and the recent COVID-19 pandemic, which are characterized by rapid transmission, high pathogenicity, and frequent mutations, posing a serious threat to human health. These viruses are mediated by fusion proteins at the early stage for infecting host cells, and the six-helix bundle (6-HB) formed by fusion protein conformational change is the crucial structure for viral membrane fusion and the target for fusion inhibitors. Small molecule fusion inhibitors, compared to peptide-based agents, offer advantages including superior oral bioavailability, metabolic stability, and lower production cost, thereby potentially reducing resistance risk. Their mechanism of targeting conserved fusion machinery highlights potential for developing broad-spectrum agents, as evidenced by activity against distinct viruses such as HIV and coronaviruses. Thus, the development of small-molecule fusion inhibitors has become an important breakthrough for antiviral agent research and development. This narrative review summarizes the research progress of small-molecule fusion inhibitors targeting viral fusion proteins (such as HIV envelope protein, coronavirus spike protein, influenza virus hemagglutinin), aiming to provide novel design pathways based on fusion inhibition strategies and fresh perspectives on antiviral R&D.
- 21 July 2026
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 33, 1-23
Research and Development of Small Molecule Fusion Inhibitors Against Viruses
The Type I enveloped viruses (such as HIV, coronavirus, influenza virus, etc.) have caused significant public health events globally, including AIDS, influenza pandemics, and the recent COVID-19 pandemic, which are characterized by rapid transmission, high pathogenicity, and frequent mutations, posing a serious threat to human health. These viruses are mediated by fusion proteins at the early stage for infecting host cells, and the six-helix bundle (6-HB) formed by fusion protein conformational change is the crucial structure for viral membrane fusion and the target for fusion inhibitors. Small molecule fusion inhibitors, compared to peptide-based agents, offer advantages including superior oral bioavailability, metabolic stability, and lower production cost, thereby potentially reducing resistance risk. Their mechanism of targeting conserved fusion machinery highlights potential for developing broad-spectrum agents, as evidenced by activity against distinct viruses such as HIV and coronaviruses. Thus, the development of small-molecule fusion inhibitors has become an important breakthrough for antiviral agent research and development. This narrative review summarizes the research progress of small-molecule fusion inhibitors targeting viral fusion proteins (such as HIV envelope protein, coronavirus spike protein, influenza virus hemagglutinin), aiming to provide novel design pathways based on fusion inhibition strategies and fresh perspectives on antiviral R&D.
- Open Access
Discovery of Novel SARS-CoV-2 Fusion Inhibitors—Posaconazole-Polyarginine Conjugates
Objectives: The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the current treatment limitations—particularly the emergence of drug resistance and the reduced efficacy of some existing drugs against new variants—highlight the need for novel antiviral strategies with novel action mechanisms. Fusion inhibitors that disrupt six-helix bundle (6-HB) formation during viral entry represent a promising approach. Posaconazole, an antifungal agent, has been identified as a weak fusion inhibitor, but suffers from poor membrane permeability and modest activity. This study aimed to enhance its antiviral potency by conjugating it with cell-penetrating polyarginine peptides and to investigate the mechanism of action. Methods: A series of posaconazole-polyarginine conjugates were synthesized via click chemistry. Antiviral activity was evaluated using pseudotyped SARS-CoV-2 Omicron XDV in HEK293T cells. Mechanisms were investigated by circular dichroism, native PAGE, size-exclusion HPLC, molecular docking, and isothermal titration calorimetry. Metabolic stability was assessed using hepatic microsomes. Results: Posa-R8 exhibited potent antiviral activity comparable to the clinical candidate EK1, with minimal cytotoxicity. Mechanistic studies confirmed that Posa-R8 binds the HR2 region of the spike protein, disrupts 6-HB formation, and inhibits membrane fusion. It also showed strong lipid bilayer affinity and improved phase I metabolic stability over EK1. Conclusions: Polyarginine conjugation enhances the membrane-binding affinity and antiviral efficacy of posaconazole. Posa-R8 represents a promising lead for developing next-generation SARS-CoV-2 fusion inhibitors.
Open AccessDiscovery of Novel SARS-CoV-2 Fusion Inhibitors—Posaconazole-Polyarginine Conjugates
Objectives: The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the current treatment limitations—particularly the emergence of drug resistance and the reduced efficacy of some existing drugs against new variants—highlight the need for novel antiviral strategies with novel action mechanisms. Fusion inhibitors that disrupt six-helix bundle (6-HB) formation during viral entry represent a promising approach. Posaconazole, an antifungal agent, has been identified as a weak fusion inhibitor, but suffers from poor membrane permeability and modest activity. This study aimed to enhance its antiviral potency by conjugating it with cell-penetrating polyarginine peptides and to investigate the mechanism of action. Methods: A series of posaconazole-polyarginine conjugates were synthesized via click chemistry. Antiviral activity was evaluated using pseudotyped SARS-CoV-2 Omicron XDV in HEK293T cells. Mechanisms were investigated by circular dichroism, native PAGE, size-exclusion HPLC, molecular docking, and isothermal titration calorimetry. Metabolic stability was assessed using hepatic microsomes. Results: Posa-R8 exhibited potent antiviral activity comparable to the clinical candidate EK1, with minimal cytotoxicity. Mechanistic studies confirmed that Posa-R8 binds the HR2 region of the spike protein, disrupts 6-HB formation, and inhibits membrane fusion. It also showed strong lipid bilayer affinity and improved phase I metabolic stability over EK1. Conclusions: Polyarginine conjugation enhances the membrane-binding affinity and antiviral efficacy of posaconazole. Posa-R8 represents a promising lead for developing next-generation SARS-CoV-2 fusion inhibitors.
- 1 June 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (6) , e70298
Structural Optimization Strategy for α,β ‐Unsaturated Ketone TrxR Inhibitors: From Enhanced Pharmacokinetics to Improved Tumor Selectivity
Thioredoxin reductase (TrxR), a master regulator of intracellular redox homeostasis, is a validated antitumor target. α,β ‐Unsaturated ketones are potent irreversible TrxR inhibitors with robust in vitro anticancer activity, yet their clinical translation is hindered by critical druggability deficits: poor pharmacokinetics (low solubility, metabolic instability, and low bioavailability) and insufficient tumor selectivity (off‐target toxicity and weak tumor tropism). This review systematically summarizes structural optimization strategies to address these limitations. To improve pharmacokinetics, core tactics include introducing polar heterocycles/hydrophilic groups, modifying skeletons, replacing labile moieties, and hybridizing pharmacophores with subcellular targeting motifs. To enhance tumor selectivity, electronic effect modulation, lipophilicity tuning, scaffold rigidification, tumor‐targeting moiety conjugation, and electrophilic center regulation reduce off‐target effects. Additionally, tumor‐specific redox properties are harnessed to boost intratumoral enrichment. The review further highlights current limitations (e.g., overreliance on natural product modifications, lack of universal SAR frameworks, and inadequate ADME regulation) and prospects future directions: structure‐based rational design, tumor microenvironment‐responsive prodrugs, multi‐target synergism, reversible‐irreversible switchable inhibitors, and nanodelivery integration. Collectively, these optimizations lay a theoretical foundation for developing safe, effective TrxR inhibitors to advance precision cancer therapy.
- 1 June 2026
- Published by Wiley in Archiv der Pharmazie
- Vol. 359 (6) , e70298
Structural Optimization Strategy for α,β ‐Unsaturated Ketone TrxR Inhibitors: From Enhanced Pharmacokinetics to Improved Tumor Selectivity
Thioredoxin reductase (TrxR), a master regulator of intracellular redox homeostasis, is a validated antitumor target. α,β ‐Unsaturated ketones are potent irreversible TrxR inhibitors with robust in vitro anticancer activity, yet their clinical translation is hindered by critical druggability deficits: poor pharmacokinetics (low solubility, metabolic instability, and low bioavailability) and insufficient tumor selectivity (off‐target toxicity and weak tumor tropism). This review systematically summarizes structural optimization strategies to address these limitations. To improve pharmacokinetics, core tactics include introducing polar heterocycles/hydrophilic groups, modifying skeletons, replacing labile moieties, and hybridizing pharmacophores with subcellular targeting motifs. To enhance tumor selectivity, electronic effect modulation, lipophilicity tuning, scaffold rigidification, tumor‐targeting moiety conjugation, and electrophilic center regulation reduce off‐target effects. Additionally, tumor‐specific redox properties are harnessed to boost intratumoral enrichment. The review further highlights current limitations (e.g., overreliance on natural product modifications, lack of universal SAR frameworks, and inadequate ADME regulation) and prospects future directions: structure‐based rational design, tumor microenvironment‐responsive prodrugs, multi‐target synergism, reversible‐irreversible switchable inhibitors, and nanodelivery integration. Collectively, these optimizations lay a theoretical foundation for developing safe, effective TrxR inhibitors to advance precision cancer therapy.
- Open Access
- 14 May 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (5) , 602
Disulfide Cross-Linked Thiolated Chitosan/Oxidized Dextran–Oleylamine Micelle–Hydrogel System with pH/ROS Dual-Responsive Cascade Drug Release for Integrated Colon Targeting and Mucosal Repair in Inflammatory Bowel Disease
Background: Oral colon-targeted delivery for inflammatory bowel disease (IBD) faces significant challenges, including limited gastrointestinal stability, premature drug release, and insufficient mucosal retention. Methods: To address these limitations, a mucoadhesive polysaccharide-based composite hydrogel incorporating prednisolone-loaded polymeric micelles was developed to enhance colonic delivery and promote mucosal repair. Amphiphilic oxidized dextran–oleylamine (ODEX-OA) copolymers were synthesized to self-assemble into prednisolone-loaded micelles. These micelles were subsequently embedded within a thiolated chitosan (CSSH) hydrogel through a Schiff base reaction, yielding the ODEX-OA-Pred-CSSH composite. The resulting system was comprehensively characterized for particle size, mucoadhesion, degradation, and pH/ROS dual-responsive drug release. Its colon-targeting capability and therapeutic efficacy were subsequently assessed in a dextran sulfate sodium (DSS)-induced colitis mouse model. Results: In vitro, the composite hydrogel demonstrated nanoscale micellar size, enhanced drug release kinetics under simulated inflammatory colonic conditions, and prolonged colonic retention for up to 24 h following oral administration. In vivo, studies confirmed that ODEX-OA-Pred-CSSH significantly alleviated colitis, evidenced by a reduced disease activity index, diminished pro-inflammatory cytokine levels, restored colon length, decreased spleen index, and improved histological mucosal repair. Conclusions: These findings collectively suggest that this mucoadhesive micelle–hydrogel composite represents a promising and effective oral colon-targeted platform for the treatment of IBD.
- 14 May 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (5) , 602
Open AccessDisulfide Cross-Linked Thiolated Chitosan/Oxidized Dextran–Oleylamine Micelle–Hydrogel System with pH/ROS Dual-Responsive Cascade Drug Release for Integrated Colon Targeting and Mucosal Repair in Inflammatory Bowel Disease
Background: Oral colon-targeted delivery for inflammatory bowel disease (IBD) faces significant challenges, including limited gastrointestinal stability, premature drug release, and insufficient mucosal retention. Methods: To address these limitations, a mucoadhesive polysaccharide-based composite hydrogel incorporating prednisolone-loaded polymeric micelles was developed to enhance colonic delivery and promote mucosal repair. Amphiphilic oxidized dextran–oleylamine (ODEX-OA) copolymers were synthesized to self-assemble into prednisolone-loaded micelles. These micelles were subsequently embedded within a thiolated chitosan (CSSH) hydrogel through a Schiff base reaction, yielding the ODEX-OA-Pred-CSSH composite. The resulting system was comprehensively characterized for particle size, mucoadhesion, degradation, and pH/ROS dual-responsive drug release. Its colon-targeting capability and therapeutic efficacy were subsequently assessed in a dextran sulfate sodium (DSS)-induced colitis mouse model. Results: In vitro, the composite hydrogel demonstrated nanoscale micellar size, enhanced drug release kinetics under simulated inflammatory colonic conditions, and prolonged colonic retention for up to 24 h following oral administration. In vivo, studies confirmed that ODEX-OA-Pred-CSSH significantly alleviated colitis, evidenced by a reduced disease activity index, diminished pro-inflammatory cytokine levels, restored colon length, decreased spleen index, and improved histological mucosal repair. Conclusions: These findings collectively suggest that this mucoadhesive micelle–hydrogel composite represents a promising and effective oral colon-targeted platform for the treatment of IBD.
- 11 May 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (9) , e70300
Design and Evaluation of Tyrosine‐Rich Antimicrobial Peptides With Quadruple Repeating Units
Multidrug‐resistant (MDR) bacteria pose a significant threat to global public health by undermining conventional antibiotics. Antimicrobial peptides (AMPs), with their membrane‐targeting mechanisms, offer a promising alternative; however, the clinical translation of natural AMPs is hampered by systemic toxicity and high synthesis costs. This study introduces a novel strategy based on a quadruple repeating unit (A 1 A 2 B 1 B 2 ) n , employing tyrosine (Y) as a key hydrophobic residue to reduce overall hydrophobicity and hemolytic activity while maintaining antimicrobial efficacy. The candidate peptide (RRLY) 4 exhibited broad‐spectrum antimicrobial activity against reference strains (minimum inhibitory concentrations (MICs): 15.63–125 μg/mL), combined with low hemolytic activity (HC 50 > 1500 μg/mL) and a therapeutic index exceeding 31.66. Furthermore, (RRLY) 4 possessed potent antimicrobial effects against five clinically isolated MDR bacteria, with MICs ranging from 15.63 to 31.25 μg/mL, and also showed low salt sensitivity. Additionally, mechanism of action studies revealed that (RRLY) 4 exerted rapid bactericidal activity by disrupting the membrane integrity of Staphylococcus aureus ATCC 25 923 and Escherichia coli ATCC 25 922. This study demonstrates that tyrosine can serve as a hydrophobic residue in the rational design of AMPs, offers a strategy for developing amphipathic AMPs with potent antimicrobial activity and low hemolytic activity.
- 11 May 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (9) , e70300
Design and Evaluation of Tyrosine‐Rich Antimicrobial Peptides With Quadruple Repeating Units
Multidrug‐resistant (MDR) bacteria pose a significant threat to global public health by undermining conventional antibiotics. Antimicrobial peptides (AMPs), with their membrane‐targeting mechanisms, offer a promising alternative; however, the clinical translation of natural AMPs is hampered by systemic toxicity and high synthesis costs. This study introduces a novel strategy based on a quadruple repeating unit (A 1 A 2 B 1 B 2 ) n , employing tyrosine (Y) as a key hydrophobic residue to reduce overall hydrophobicity and hemolytic activity while maintaining antimicrobial efficacy. The candidate peptide (RRLY) 4 exhibited broad‐spectrum antimicrobial activity against reference strains (minimum inhibitory concentrations (MICs): 15.63–125 μg/mL), combined with low hemolytic activity (HC 50 > 1500 μg/mL) and a therapeutic index exceeding 31.66. Furthermore, (RRLY) 4 possessed potent antimicrobial effects against five clinically isolated MDR bacteria, with MICs ranging from 15.63 to 31.25 μg/mL, and also showed low salt sensitivity. Additionally, mechanism of action studies revealed that (RRLY) 4 exerted rapid bactericidal activity by disrupting the membrane integrity of Staphylococcus aureus ATCC 25 923 and Escherichia coli ATCC 25 922. This study demonstrates that tyrosine can serve as a hydrophobic residue in the rational design of AMPs, offers a strategy for developing amphipathic AMPs with potent antimicrobial activity and low hemolytic activity.
- Open Access
- 10 March 2026
- Published by Elsevier in SSRN Electronic Journal
5-acetyl-N-(1H-pyrazol-5-yl)furan-2-carboxamide as a novel oral available urea transporter inhibitor with improved properties
Urea transporter (UT), as a novel diuretic target, allows its inhibitors to selectively excrete urea without affecting electrolyte balance, making them suitable for long-term therapy. Based on the orally available UT inhibitors Y02 and Y32 with diarylamide scaffold that we developed in previous studies, 12f, with improved diuretic efficiency and physiochemical properties, is discovered in this work. In vitro UT-B inhibitory activity testing revealed that 12f inhibited mouse UT-B and rat UT-B with IC50 value of 0.11 μM and 0.054 μM, representing 14 times and 8 times potency increases over Y32, 15 times and 12 times increases over Y02, respectively. In vivo diuretic effect investigation showed significant raise of urine output in rats orally administered 12f in both 100 mg/kg and 50 mg/kg doses. Most interestingly, the diuretic effect can last for up to 24~40 hours, which is much longer than that of Y02, suggesting sustained therapeutic efficacy through stable drug concentrations and improved patient adherence by reducing dosing frequency. Molecular docking study indicated that 12f formed multidimensional interactions with the active binding site of UT proteins and the binding energy to UT-A2 is stronger than to UT-B, implying a possibly higher inhibitory effect to UT-A families which is beneficial for diuretic activity. Additionally, the water solubility of 12f was 5 times and 18 times that of Y32 and Y02, respectively, suggesting a superior in vivo transport characteristic. Furthermore, by replacing nitro-group of Y02 and Y32, which has potential genotoxicity, to acetyl, 12f may exhibit a better safety profile. Therefore, 12f, as an oral available salt-sparing diuretic targeting urea transporter inhibitor, has an excellent potential for development as a promising candidate for treatment of diseases that require long-term usage of diuretic.
- 10 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open Access5-acetyl-N-(1H-pyrazol-5-yl)furan-2-carboxamide as a novel oral available urea transporter inhibitor with improved properties
Urea transporter (UT), as a novel diuretic target, allows its inhibitors to selectively excrete urea without affecting electrolyte balance, making them suitable for long-term therapy. Based on the orally available UT inhibitors Y02 and Y32 with diarylamide scaffold that we developed in previous studies, 12f, with improved diuretic efficiency and physiochemical properties, is discovered in this work. In vitro UT-B inhibitory activity testing revealed that 12f inhibited mouse UT-B and rat UT-B with IC50 value of 0.11 μM and 0.054 μM, representing 14 times and 8 times potency increases over Y32, 15 times and 12 times increases over Y02, respectively. In vivo diuretic effect investigation showed significant raise of urine output in rats orally administered 12f in both 100 mg/kg and 50 mg/kg doses. Most interestingly, the diuretic effect can last for up to 24~40 hours, which is much longer than that of Y02, suggesting sustained therapeutic efficacy through stable drug concentrations and improved patient adherence by reducing dosing frequency. Molecular docking study indicated that 12f formed multidimensional interactions with the active binding site of UT proteins and the binding energy to UT-A2 is stronger than to UT-B, implying a possibly higher inhibitory effect to UT-A families which is beneficial for diuretic activity. Additionally, the water solubility of 12f was 5 times and 18 times that of Y32 and Y02, respectively, suggesting a superior in vivo transport characteristic. Furthermore, by replacing nitro-group of Y02 and Y32, which has potential genotoxicity, to acetyl, 12f may exhibit a better safety profile. Therefore, 12f, as an oral available salt-sparing diuretic targeting urea transporter inhibitor, has an excellent potential for development as a promising candidate for treatment of diseases that require long-term usage of diuretic.
- Open Access
- 12 December 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (12) , 1881
Design of Artificial Peptide Against HIV-1 Based on the Heptad-Repeat Rules and Membrane-Anchor Strategies
Objective: The six-helix bundle (6-HB) is critical for HIV-1 membrane fusion. To disrupt this process, peptide inhibitors have been meticulously designed to target interactions within the 6-HB regions, thereby blocking membrane fusion and exerting inhibitory effects. Current peptide inhibitors like Enfuvirtide suffer from drug resistance and short in vivo half-life. This study aims to design novel anti-HIV-1 peptides by integrating heptad-repeat rules and membrane-anchor strategies. Methods: Artificial peptides were designed using HR rules from the HIV-1 gp41 6-HB motif and membrane-anchor modifications. Results: EK35S-Palm has emerged as a highly promising candidate for HIV-1 inhibition, exhibiting robust binding affinity to the target and effectively impeding the 6-HB spontaneous formation. Discussion: HR-based design avoids viral sequence homology, and membrane anchoring enhances local agent concentration, improving pharmacokinetics. The HR binding and membrane stabilization of EK35S-Palm provide synergistic inhibition. Conclusions: Integrating HR structural design with membrane-anchor strategies yields potent HIV-1 fusion inhibitors. EK35S-Palm demonstrates superior efficacy and stability over current therapies. These approaches hold great potential for overcoming the current therapy limitations and advancing the more effective and durable HIV-1 fusion inhibitors.
- 12 December 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (12) , 1881
Open AccessDesign of Artificial Peptide Against HIV-1 Based on the Heptad-Repeat Rules and Membrane-Anchor Strategies
Objective: The six-helix bundle (6-HB) is critical for HIV-1 membrane fusion. To disrupt this process, peptide inhibitors have been meticulously designed to target interactions within the 6-HB regions, thereby blocking membrane fusion and exerting inhibitory effects. Current peptide inhibitors like Enfuvirtide suffer from drug resistance and short in vivo half-life. This study aims to design novel anti-HIV-1 peptides by integrating heptad-repeat rules and membrane-anchor strategies. Methods: Artificial peptides were designed using HR rules from the HIV-1 gp41 6-HB motif and membrane-anchor modifications. Results: EK35S-Palm has emerged as a highly promising candidate for HIV-1 inhibition, exhibiting robust binding affinity to the target and effectively impeding the 6-HB spontaneous formation. Discussion: HR-based design avoids viral sequence homology, and membrane anchoring enhances local agent concentration, improving pharmacokinetics. The HR binding and membrane stabilization of EK35S-Palm provide synergistic inhibition. Conclusions: Integrating HR structural design with membrane-anchor strategies yields potent HIV-1 fusion inhibitors. EK35S-Palm demonstrates superior efficacy and stability over current therapies. These approaches hold great potential for overcoming the current therapy limitations and advancing the more effective and durable HIV-1 fusion inhibitors.
- 30 October 2025
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (1) , 1-17
Preparation and Optimization of Pramipexole Hydrochloride Solid Dispersions to Improve Drug Release and Bioavailability
Pramipexole dihydrochloride (PPX) is a Biopharmaceutical Classification System (BCS) Class I drug with a short half-life, and its aqueous solution is susce
- 30 October 2025
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (1) , 1-17
Preparation and Optimization of Pramipexole Hydrochloride Solid Dispersions to Improve Drug Release and Bioavailability
Pramipexole dihydrochloride (PPX) is a Biopharmaceutical Classification System (BCS) Class I drug with a short half-life, and its aqueous solution is susce
- 1 August 2025
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 32 (25) , 5321-5337
Structural Basis of HIV-1 gp41 N-trimer for Designing Bifunctional Peptide-based Fusion Inhibitors
Background: Pathogenic viruses that cause large-scale global or regional outbreaks almost always contain class I fusion proteins. Although the viruses differ in morphology, they all require fusion protein-mediated virus-host cell membranes during the early stages of host cell invasion. Methods: The CHR region and NHR region of fusion proteins can form the 6-HB structure to drive the fusion pore formation between viruses and host cells through metastable interactions. Here, we obtained bifunctional N-peptides with inhibitory activities against two viruses, HIV-1 and MERS-CoV, based on the sequences in the HIV-1 NHR region by constructing N-trimer conformation interacting with the CHR region. Results: This study demonstrates that N-peptides with the coiled triple helix structure obtained from the NHR region in 6-HB are able to target the CHR region and exhibit inhibitory activity against a variety of viruses. Conclusion: Moreover, this strategy can be used to investigate antivirals against unknown viruses for future outbreaks.
- 1 August 2025
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 32 (25) , 5321-5337
Structural Basis of HIV-1 gp41 N-trimer for Designing Bifunctional Peptide-based Fusion Inhibitors
Background: Pathogenic viruses that cause large-scale global or regional outbreaks almost always contain class I fusion proteins. Although the viruses differ in morphology, they all require fusion protein-mediated virus-host cell membranes during the early stages of host cell invasion. Methods: The CHR region and NHR region of fusion proteins can form the 6-HB structure to drive the fusion pore formation between viruses and host cells through metastable interactions. Here, we obtained bifunctional N-peptides with inhibitory activities against two viruses, HIV-1 and MERS-CoV, based on the sequences in the HIV-1 NHR region by constructing N-trimer conformation interacting with the CHR region. Results: This study demonstrates that N-peptides with the coiled triple helix structure obtained from the NHR region in 6-HB are able to target the CHR region and exhibit inhibitory activity against a variety of viruses. Conclusion: Moreover, this strategy can be used to investigate antivirals against unknown viruses for future outbreaks.